Liquidia Shares Climb to All-Time High Amid Surging Revenue

Dow Jones

May 12

By Christopher Kuo

Liquidia shares rose to an all-time high as the company's product sales drove a surge in first-quarter revenue.

Shares of the biopharmaceutical company focused on cardiopulmonary diseases rose 17% on Monday to $49.56. The stock reached an all-time high of $50.50 on Monday.

The company posted a first-quarter profit of $52.9 million, or 52 cents a share, compared with a profit of $38.4 million, or 45 cents a share, a year earlier. Analysts polled by FactSet expected 41 cents a share.

Revenue climbed to $132.9 million from $3.1 million a year earlier. Analysts expected $119.4 million. The growth was driven by sales of the Yutrepia treatment for pulmonary hypertension. Product sales of Yutrepia were $129.9 million in the quarter, the company said.

The company began shipping Yutrepia to U.S. customers in June, following approval by the Food and Drug Administration on May 23, 2025.

Write to Christopher Kuo at chris.kuo@wsj.com

(END) Dow Jones Newswires

May 11, 2026 12:36 ET (16:36 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2634235023"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2634235023\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2634235023?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-12 00:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2634235023","market":"nz","top_or_hot":-1,"title":"Liquidia Shares Climb to All-Time High Amid Surging Revenue","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Liquidia shares rose to an all-time high as the company's product sales drove a surge in first-quarter revenue. \n</p>\n<p>\n  Shares of the biopharmaceutical company focused on cardiopulmonary diseases rose 17% on Monday to $49.56. The stock reached an all-time high of $50.50 on Monday. \n</p>\n<p>\n  The company posted a first-quarter profit of $52.9 million, or 52 cents a share, compared with a profit of $38.4 million, or 45 cents a share, a year earlier. Analysts polled by FactSet expected 41 cents a share. \n</p>\n<p>\n  Revenue climbed to $132.9 million from $3.1 million a year earlier. Analysts expected $119.4 million. The growth was driven by sales of the Yutrepia treatment for pulmonary hypertension. Product sales of Yutrepia were $129.9 million in the quarter, the company said. \n</p>\n<p>\n  The company began shipping Yutrepia to U.S. customers in June, following approval by the Food and Drug Administration on May 23, 2025. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 11, 2026 12:36 ET (16:36 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Liquidia Shares Climb to All-Time High Amid Surging Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLiquidia Shares Climb to All-Time High Amid Surging Revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-12 00:36</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Liquidia shares rose to an all-time high as the company's product sales drove a surge in first-quarter revenue. \n</p>\n<p>\n  Shares of the biopharmaceutical company focused on cardiopulmonary diseases rose 17% on Monday to $49.56. The stock reached an all-time high of $50.50 on Monday. \n</p>\n<p>\n  The company posted a first-quarter profit of $52.9 million, or 52 cents a share, compared with a profit of $38.4 million, or 45 cents a share, a year earlier. Analysts polled by FactSet expected 41 cents a share. \n</p>\n<p>\n  Revenue climbed to $132.9 million from $3.1 million a year earlier. Analysts expected $119.4 million. The growth was driven by sales of the Yutrepia treatment for pulmonary hypertension. Product sales of Yutrepia were $129.9 million in the quarter, the company said. \n</p>\n<p>\n  The company began shipping Yutrepia to U.S. customers in June, following approval by the Food and Drug Administration on May 23, 2025. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 11, 2026 12:36 ET (16:36 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LQDA","symbol_name":"Liquidia Technologies Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2634235023","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2634235023","pubTimestamp":1778517360,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Liquidia shares rose to an all-time high as the company's product sales drove a surge in first-quarter revenue.Shares of the biopharmaceutical company focused on cardiopulmonary diseases rose 17% on Monday to $49.56. The stock reached an all-time high of $50.50 on Monday.The company posted a first-quarter profit of $52.9 million, or 52 cents a share, compared with a profit of $38.4 million, or 45 cents a share, a year earlier. Analysts polled by FactSet expected 41 cents a share.Revenue climbed to $132.9 million from $3.1 million a year earlier. Analysts expected $119.4 million. The growth was driven by sales of the Yutrepia treatment for pulmonary hypertension. Product sales of Yutrepia were $129.9 million in the quarter, the company said.The company began shipping Yutrepia to U.S. customers in June, following approval by the Food and Drug Administration on May 23, 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LQDA":"Liquidia Technologies Inc","BK4007":"制药"},"translate_title":"收入激增，Liquidia股价攀升至历史新高","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LQDA":0.9},"content_text":"By Christopher Kuo \n\n\n \n\n\n  Liquidia shares rose to an all-time high as the company's product sales drove a surge in first-quarter revenue. \n\n\n  Shares of the biopharmaceutical company focused on cardiopulmonary diseases rose 17% on Monday to $49.56. The stock reached an all-time high of $50.50 on Monday. \n\n\n  The company posted a first-quarter profit of $52.9 million, or 52 cents a share, compared with a profit of $38.4 million, or 45 cents a share, a year earlier. Analysts polled by FactSet expected 41 cents a share. \n\n\n  Revenue climbed to $132.9 million from $3.1 million a year earlier. Analysts expected $119.4 million. The growth was driven by sales of the Yutrepia treatment for pulmonary hypertension. Product sales of Yutrepia were $129.9 million in the quarter, the company said. \n\n\n  The company began shipping Yutrepia to U.S. customers in June, following approval by the Food and Drug Administration on May 23, 2025. \n\n\n \n\n\n  Write to Christopher Kuo at chris.kuo@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 11, 2026 12:36 ET (16:36 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}